What BiPER Therapeutics does

BiPER Therapeutics SAS is a preclinical-stage French biotech founded in 2021 and headquartered in Strasbourg (32 Allée de la Robertsau), with a planned R&D center in Hammamet, Tunisia announced in December 2025. The company is developing first-in-class selective small-molecule inhibitors of BiP (also known as GRP78 or HSPA5), a chaperone protein of the unfolded protein response that is overexpressed in more than 50% of cancer patients. Its lead candidate BPR001-615 selectively binds GRP78 in cancer cells and induces lethal unresolved endoplasmic reticulum (ER) stress, triggering apoptosis and autophagy, with demonstrated preclinical efficacy in monotherapy and in combination with chemotherapies, targeted therapies, and immunotherapies. BPR001-615 is positioned as an oral, biomarker-stratified therapy initially targeting gastrointestinal cancers and is currently in IND-enabling studies; the pipeline also includes BPR002 (solid tumors with immunomodulation properties) and BPR003 (BiP modulators for non-oncology indications). BiPER pursues a precision medicine approach using a non-invasive circulating BiP biomarker measured by plasma ELISA to stratify patients.

The company has no commercial products and generates no revenue. Its go-to-market motion is enterprise partnership and out-licensing rather than direct sales: BiPER seeks collaborations with larger pharmaceutical and biotech companies for co-development, combination strategies, and global commercialization, given the preclinical stage of development. The company is led by CEO Mehdi Chelbi (with co-founders Stéphane Rocchi, Rachid Benhida, and Cyril Ronco), supported by a Scientific Advisory Board that includes Pr Amy S Lee (a foundational GRP78 researcher at USC Keck), Dr Neil Sankhar (clinical lead on Kadcyla and Ibrutinib NDAs), and senior French oncologists. The team is complemented by collaborations with premier French academic centers, including the Mediterranean Center for Molecular Medicine (C3M) in Nice, Gustave Roussy Institute, and APHP Cochin. Capital sources are predominantly French public and private backers including Bpifrance, Région Grand Est, WiSEED, and Medin Fund Management Co, with approximately €2.25 million disclosed across seed and December 2025 rounds, supplemented by additional tranches in December 2024 and December 2025.

Name

BiPER Therapeutics

Legal name

BiPER Therapeutics SAS

Website

https://biper-tx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

BiPER Therapeutics is a preclinical French biotech developing first-in-class selective BiP (GRP78) small-molecule inhibitors for cancer, with lead candidate BPR001-615 in IND-enabling studies for gastrointestinal cancers and additional programs in solid tumors and non-oncology indications using a circulating BiP biomarker for patient stratification.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Predictive Biomarkers for Therapy Selection (response/non-response stratification) (HLAAAMAE), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Digestive Oncology (GI Cancer Care) (HLAKAEAF), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Targeted cancer therapy
• Small molecule oncology
• GRP78 BiP inhibitors
• Precision oncology drugs
• Preclinical drug development

Headquarters

HQ city

Strasbourg

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BiPER Therapeutics develops a pipeline of first-in-class selective BiP (GRP78) small-molecule inhibitors designed as targeted cancer therapy. The lead candidate BPR001-615 selectively binds GRP78 to induce lethal unresolved ER stress in cancer cells, causing apoptosis and autophagy, with applications in gastrointestinal cancers. Two additional candidates (BPR002 for solid tumors with immunomodulation; BPR003 for non-oncology indications) and a non-invasive circulating BiP biomarker for precision medicine patient stratification complement the platform.

Product overview

BiPER Therapeutics develops a pipeline of first-in-class selective BiP (GRP78) inhibitors as targeted cancer therapies. The company's core platform consists of small molecules that induce unresolved endoplasmic reticulum (ER) stress in cancer cells, causing them to 'burn out' through apoptosis and autophagy. The pipeline includes three candidates: BPR001-615 (lead candidate for gastrointestinal cancers in IND-enabling stage), BPR002 (for solid tumors with immunomodulation properties), and BPR003 (for non-oncology indications). The company employs a precision medicine approach using BiP as a non-invasive circulating biomarker detectable via plasma ELISA test for patient stratification.

Differentiator

Problem solved

Functional benefit

Products and services

• BPR001-615 First-in-class small molecule targeting GRP78/BiP designed as an oral anti-cancer therapy for gastrointestinal cancers. Selectively kills cancer cells by inducing strong and lethal ER stress through selective GRP78 binding and inhibition, leading to apoptosis and autophagy. Demonstrated efficacy as monotherapy and in combination with chemotherapies, targeted therapies and immunotherapies, with oral bioavailability and an excellent tolerability profile. Currently in IND-enabling stage.
• BPR002 First-in-class small molecule series inducing ER stress associated with strong immunomodulation properties. Leads are selected based on immune-cell mediated cancer-cell killing properties, targeting solid tumors. Currently in Lead Selection stage.
• BPR003 Pipeline program focused on identifying BiP modulators designed to re-establish homeostasis balance in non-oncology indications where endogenous protective mechanisms are frequently dysregulated. Aims to enable healthy cells to cease being pathological and change the course of disease. Indication is undisclosed.

Quantifiable outcome

• Efficacy demonstrated in broad range of cancer indications in monotherapy and combination with excellent pharmacological and tolerability profile
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Premier Academic CenterscoreStrategic or Co-development PartnerBiPER Therapeutics has extensive collaborations with premier academic centers for scientific validation and translation of discoveries into clinical candidates. Key academic partners include Mediterranean Center for Molecular Medicine (C3M, Nice), Gustave Roussy Institute, Nice University Hospital Dermatology Department, and Paris Hospitals (APHP) Cochin site. These partnerships provide rigorous scientific validation and accelerate pipeline development.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Aprea Therapeutics: Clinical-stage precision oncology biotech developing small molecules targeting cancer cell stress and DNA damage pathways. Comparable as a small-cap precision oncology company advancing targeted small molecules through early clinical development.
• Erasca: Precision oncology biotech developing small molecule inhibitors targeting the RAS/MAPK pathway. Comparable as an emerging precision oncology company with multiple pipeline programs and biomarker-driven development strategy.
• Tango Therapeutics: Precision oncology biotech leveraging synthetic lethality to develop targeted cancer therapies. Comparable as a clinical-stage targeted oncology company with multi-asset pipeline and platform-driven approach.

Regional players

• Inventiva: French clinical-stage biotech developing small molecule therapies for oncology and other indications. Comparable as a French-listed biotech developing small molecules targeting cancer and other diseases, similar operating geography and stage.
• Innate Pharma: French clinical-stage immuno-oncology biotech developing antibody-based therapeutics. Comparable as a French oncology biotech advancing multiple programs through clinical development with similar European operational base.
• Transgene: French clinical-stage oncology biotech developing immunotherapies including oncolytic viruses and cancer vaccines. Comparable as a French oncology biotech with multi-program pipeline targeting solid tumors.

Emerging players

• Cardiff Oncology: Clinical-stage oncology company developing targeted therapies for cancer with biomarker-driven patient selection. Comparable as an emerging precision oncology biotech with biomarker-guided development strategy.

Broad incumbents

• Roche: Global pharmaceutical leader with major oncology franchise including targeted therapies and immunotherapies. Comparable as a potential strategic partner and benchmark for combination strategy in GI cancers where Roche is heavily invested.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biper-therapeutics/posts/?feedView=all

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiPER Therapeutics